Comanche gets $40M more to test its preeclampsia siRNAnews2026-01-05T11:30:31+00:00January 5th, 2026|Endpoints News|
Servier taps Insilico’s AI platform for early cancer R&Dnews2026-01-05T10:34:25+00:00January 5th, 2026|Endpoints News|
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cashnews2026-01-05T10:09:50+00:00January 5th, 2026|Endpoints News|
AbbVie does T cell engager deal in China for Zelgen’s DLL3-targeted drugnews2025-12-31T16:18:48+00:00December 31st, 2025|Endpoints News|
Vanda wins FDA approval for motion sickness drug news2025-12-31T15:47:05+00:00December 31st, 2025|Endpoints News|
FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndromenews2025-12-31T15:20:26+00:00December 31st, 2025|Endpoints News|
Biotech’s groove is back for 2026 as XBI surges on M&A and lower ratesnews2025-12-30T16:27:21+00:00December 30th, 2025|Endpoints News|
Insilico caps the year with a soaring Hong Kong IPOnews2025-12-30T15:29:36+00:00December 30th, 2025|Endpoints News|
Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blockernews2025-12-30T15:17:17+00:00December 30th, 2025|Endpoints News|
Federal judge blocks 340B drug pricing pilot ahead of Jan. 1 effective datenews2025-12-29T21:20:03+00:00December 29th, 2025|Endpoints News|
